Introduction
============

Colorectal cancer (CRC) is ranked as the third most common malignancy in both sexes by incidence, approximately 1.36 million per year worldwide. It is more prevalent in developed countries [@B1]. The incidence rate also increased much in Taiwan in the decades, maybe attributed to change of habit to Western-style diet [@B2],[@B3]. In the aspect of treatment strategies, there are difference between rectal cancer and colon cancer. For patients with rectal cancers invading through muscularis propria or metastasizing to regional lymph nodes, neoadjuvant concurrent chemoradiotherapy (CCRT) is gold standard in National Comprehensive Cancer Network (NCCN) Guidelines^®^[@B4]. In spite of the introduction of new strategies of therapy for the patients, CRCs are usually diagnosed in middle- or late-stage and still the fourth most common cause of cancer-related mortality, after lung, liver and gastric cancers [@B1], [@B5]. Hence, to find new prognostic factors and potential targets for treatment of CRC is imperative for scientists.

Deregulation of cellular energetics is one of the hallmarks of cancers [@B6]. Otto Heinrich Warburg, a German physiologist and laureate of Nobel Prize in Physiology or Medicine, discovered that most malignant cells generate ATPs predominantly via glycolysis and lactic acid fermentation but not tricarboxylic acid (TCA) cycle [@B7], [@B8]. This phenomenon is termed "Warburg effect", and have been long-term applied to detect malignancy [@B9]. That is positron emission tomography (PET), where fluorine-18-fludeoxyglucose (^18^F-FDG), a glucose analog, is uptaken by tissue with high glucose demand, such as cancer [@B10]. However, the genes associated with glycolysis have yet been comprehensively studied in human rectal cancer. Therefore, we analyzed a previously published transcriptomic dataset of rectal cancer (GSE35453) and focused on genes associated with glycolysis (GO:0006096). As a result, *ALDOB* was identified as the most significantly up-regulated gene.

*ALDOB* gene encodes Aldolase B (ALDOB protein), A.K.A. fructose-bisphosphate aldolase B, which plays an essential role in glycolysis and gluconeogenesis [@B11]. Aldolase B, one of three isoenzyme of human aldolase, which normally exists in liver, kidney and intestine [@B12]. The aberrant expression of Aldolase B has been investigated in hepatocellular carcinoma [@B13]-[@B16], gastric cancer [@B17] and pseudomyxoma peritonei [@B18]. To the best of our knowledge, however, the clinical significance of Aldolase B has yet been systemically studied in CRCs. Therefore, we conducted the following research.

Materials and Methods
=====================

Data mining of transcriptomic dataset of rectal cancers to identify the most up-regulated gene
----------------------------------------------------------------------------------------------

A published transcriptomic database (GSE35452), composed of 46 patients of rectal cancer doctored with preoperative chemoradiotherapy from Gene Expression Omnibus, National Center for Biotechnology Information (GEO, NCBI, Bethesda, MD, USA), was selected for research. The tumors were divided into "responder" and "non-responder" according to the response to neoadjuvant CCRT. We downloaded the raw .cel file and performed comparative analysis without filtering or preselection by the software\--Nexus Expression 3 (BioDiscovery, El Segundo, CA, USA). Under supervision, we examined the statistical significance of each transcript by comparing responder and non-responder, focusing on the genes linked to glycolysis (GO:0006096). The transcripts with expression fold change \> ± .1 log~2~ ratio and *P*-value \< .01 were selected for additional evaluation.

Study cohort of patients and specimens
--------------------------------------

The Institutional Review Board of Chi-Mei Medical Center approved this study. Totally 172 patients with primary rectal adenocarcinoma between 1998 and 2004 were enrolled from Chi-Mei Medical Center. All patients received preoperative chemoradiotherapy followed by radical proctectomy. The initial clinical staging was determined by endoscopic ultrasound (EUS) and abdominopelvic computed tomography (CT). Cases with distant metastasis at primary diagnosis (cM1), screened by chest plain film and abdominopelvic CT, were excluded. The clinical information was retrieved from the archives of medical records. The details of patient selection and the protocol of treatment were the same as preceding description [@B19].

Histopathological evaluation, immunohistochemical study and assessment of immunoreactivity
------------------------------------------------------------------------------------------

Post-CCRT staging was based on pathological examination of radical proctectomy according to 7^th^ edition of American Joint Committee on Cancer (AJCC) cancer staging system [@B20]. The grading system of tumor regression after preoperative chemoradiotherapy was evaluated in accordance with the description of Dworak *et al.*[@B21]. The method of immunohistochemistry is the same as that we reported previously [@B22]-[@B25]. Briefly speaking, paraffin-embedded tissue of pre-CCRT tumor biopsy specimens were administered the routine procedure of deparaffinization, rehydration, and epitope retrieval. Subsequently, the tissue sections were proceeded to incubation with primary antibody against ALDOB (1:100, clone EPR3137, Abcam, Cambridge, United Kingdom) for one hour. Normal liver tissues with and without incubation of ALDOB antibody were run parallel as positive and negative control, respectively. We assessed the expression of ALDOB protein by combination of the intensity and percentage of immunoreactivity in the cytoplasm of tumor cells to produce an H-score. The equation is shown below: H-score = ΣPi(i+1), in which Pi symbolizes the percentage of stained tumor cells (0%-100%) and i symbolizes the intensity of immunostain (0-3+).

Statistical tests
-----------------

IBM SPSS Statistics software, Version 22.0 (IBM Corporation, Armonk, NY, USA) was used for statistical analyses. After separating the study cohort into high- and low-expression of ALDOB (Aldolase B) by the median H-score of ALDOB immunoreactivity, Pearson\'s χ^2^ test was used for the relationship between ALDOB immunostaining and categorical important clinical and pathological parameters. Three prognostic indices---disease-specific survival (DSS), locoregional recurrent-free survival (LRFS) and metastasis-free survival (MeFS) were calculated from the days of tumor excision to those of events occurred. Kaplan-Meier survival curves compared with log-rank test was used in univariate survival analysis. Parameters with statistical significance in univariate analyses were enrolled in multivariate ones, for which, Cox model was used. For all analyses, only *P* value \< .05 was considered as statistically significant under two-tailed tests.

Results
=======

ALDOB recognized as the most significantly up-regulated gene among those belonging to glycolysis (GO:0006096)
-------------------------------------------------------------------------------------------------------------

In the public transcriptomic dataset of rectal cancer (GSE35452) from GEO, NCBI, 24 out of 46 (52.2%) patients revealed response to preoperative CCRT (responder), the rest 22 (47.8%) patients showed resistance to preoperative CCRT (non-responder). Six probes covering three transcripts associated with glycolysis (GO:0006096) were found. Of these, four probes covering *ALDOB* transcript and two probes covering *PGK1* and *LDHB* transcripts exhibited significant up- and down-regulation in non-responders than in responders, respectively (**Fig. [1](#F1){ref-type="fig"}**). The log~2~ ratios of up-regulated *ALDOB* mRNA by comparison between non-responders and responders were between 0.3209 and 1.1475 (*P* ≤ .0098, **Table [1](#T1){ref-type="table"}**).

Clinical and pathological characteristics of patients with rectal adenocarcinomas
---------------------------------------------------------------------------------

As shown in **Table [2](#T2){ref-type="table"}**, most of our patient cohort of rectal adenocarcinoma was male (62.8%, n=108) and less than 70 years old (61.6%, n=106). The invasive depth of 47.1% tumors (n=81) at pre-CCRT clinical tumor staging was limited to muscularis propria (cT1-2), and 52.9% (n=91) was beyond the muscularis propria (cT3-4). Forty-seven patients (27.3%) had nodal metastasis at pre-CCRT clinical tumor staging, and 125 patients (72.7%) didn\'t. The invasive depth of half tumors (n=86) at post-CCRT pathological tumor staging was limited to muscularis propria (ypT0-2), and the other half (n=86) was beyond the muscularis propria (ypT3-4). Forty-nine patients (28.5%) had nodal metastasis at post-CCRT pathological tumor staging, and 123 patients (71.5%) didn\'t. Lymphovascular and perineural invasion were observed in 15 (8.7%) and 5 (2.9%) tumors, respectively. The tumor response to neoadjuvant CCRT varied from grade 0-1 (n=37, 21.5%), grade 2-3 (n=118, 68.6%) and grade 4 (n=17, 9.9%).

Association between ALDOB immunoreactivity and clinical and pathological variables
----------------------------------------------------------------------------------

After dichotomizing the study cohort into ALDOB high- and low-expression groups with cutoff point of median H-score (195), we applied Pearson\'s χ^2^ test to examine the relationship between ALDOB immunostaining and variable clinical and pathological parameters. As demonstrated in **Table [2](#T2){ref-type="table"}**, ALDOB overexpression was significantly associated with more advanced post-CCRT pT status (*P* = .002), both positive pre- and post-CCRT nodal metastasis (*P* ≤ .001 for both), lymphovascular invasion (*P* = .015), perineural invasion (*P* = .023) and poor response to neoadjuvant CCRT (**Fig. [2](#F2){ref-type="fig"}**, *P* \< .001).

Survival analyses for patients with rectal adenocarcinomas
----------------------------------------------------------

In univariate analyses (**Table [3](#T3){ref-type="table"}**), more advanced post-CCRT tumor invasiveness and lower tumor regression grade were significantly correlated with shorter DSS, LRFS and MeFS intervals (*P* ≤ .009 for all). Higher pre-CCRT serum CEA level (\>5 ng/ml) and presence of lymphovascular invasion were negatively associated with DSS and LRFS to statistical significance (*P* ≤ .0216 for all). Positive pre-CCRT nodal status was significantly associated with adverse LRFS only (*P* = .007).

In multivariate analyses (**Table [4](#T4){ref-type="table"}**), tumor regression grade was an independent prognosticator for DSS (hazard ratio (HR) = 2.101, 95% confidence interval (CI): 1.001-4.425), LRFS (HR = 2.762, 95% CI: 1.241-6.173) and MeFS (HR = 2.242, 95% CI: 1.092-4.587). Lymphovascular invasion and high pre-CCRT serum CEA level were independent prognostic factor for LRFS only (HR = 3.662, 95% CI: 1.191-11.264; HR = 2.496, 95% CI: 1.061-5.876, respectively).

Prognostic significance of ALDOB overexpression in patients with rectal adenocarcinomas
---------------------------------------------------------------------------------------

High immunoreactivity of ALDOB protein (Aldolase B) was significantly correlated with poor DSS, LRFS and MeFS in univariate analyses (*P* ≤ .0075 for all, **Table [3](#T3){ref-type="table"}** and **Fig.[3](#F3){ref-type="fig"}**). High expression of ALDOB still independently predicted worse DSS and MeFS in multivariate analyses (HR = 3.462, 95% CI: 1.263-9.495; HR = 2.846, 95% CI: 1.190-6.808, respectively) (**Table [4](#T4){ref-type="table"}**).

Discussion
==========

For patients with rectal cancers, the introduction of neoadjuvant CCRT for resectable tumors not only enhances the survival rates, but also augments the possibility of curative and/or sphincter-preserving resection, as a result of down-staging of the cancer. In two important randomized controlled studies, preoperative chemoradiotherapy improved survival rates for patients with rectal cancers, which invaded through muscularis propria (cT3-4) or combined with nodal metastasis (stage II/III) [@B26], [@B27]. Although some authors promoted the "Watch and Wait Protocol" for rectal cancers with complete response to neoadjuvant chemoradiation therapy for improving the life quality of patients [@B28], nowadays, neoadjuvant CCRT followed by radical proctectomy is still gold standard treatment for patients with rectal cancers of clinical stage II and III [@B4].

Aldolase is an enzyme catabolize fructose 1,6-bisphosphate into dihydroxyacetone phosphate and glyceraldehyde 3-phosphate in the glycolysis pathway. Therefore, aldolase is also termed fructose-bisphosphate aldolase [@B11]. In vertebrates, there are three isoenzymes in the Aldolase family. Aldolase A (ALDOA) is predominantly found in the muscle tissue and erythrocytes; Aldolase B (ALDOB) in the liver, kidney an intestine; Aldolase C (ALDOC) in the central nervous system [@B12], [@B29]. Over-expression of all three isoenzymes positively regulated the canonical Wnt/β-catenin signaling pathway, a common pathway involved in carcinogenesis of CRC (30). The result indicated that all isoforms of Aldoase might serve as an oncogene in colorectal cancer [@B31]. As a key enzyme involving in glycolysis and gluconeogenesis, three isoenzymes had been investigated in cancers. Among them, most researches about Aldolase B (ALDOB) were studied in hepatocellular carcinoma. Firstly, the serum level of Aldolase B tended to be slightly elevated in patients with hepatocellular carcinoma (HCC) [@B32]. Nevertheless, down-regulation of *ALDOB* gene or Aldolase B protein were frequently observed in HCC tissues [@B13], [@B14], [@B16], [@B33]-[@B35]. Furthermore, Aldolase B under-expression in HCC was significantly associated with adverse clinico-pathological characteristics and worse recurrence-free survival and overall survival in both univariate and multivariate analyses (all *P* \< .05) [@B15]. By using HCC cell lines for *in vitro* and *in vivo* study in the same article, over-expression of Aldolase B was also negatively correlated with cell migration *in vitro* and occurrence of lung metastasis and intrahepatic metastasis, as well as the numbers of circulating tumor cells *in vivo* [@B15]. On the contrary, up-regulation and over-expression of *ALDOB* gene and Aldolase B protein were detected in human tissue of pseuomyxoma peritonei (PMP) [@B18]. The discrepancy may reflect the different biochemical statuses of the same molecules in different microenvironment of each cancer. In HCCs, the metabolic pathway of energy utilization probably changes, where Aldolase A over-expression was observed along with under-expression of Aldolase B [@B13], [@B15]. Over-expression of Aldolase B in human PMP might indicate the similar carcinogenetic processes, at least in certain aspects, between PMP and CRC, while the genetic alterations of PMP do overlap with those of CRC [@B36].

Concerning about the relationship between glycolytic enzymes and sensitivity of tumor to radiotherapy and chemotherapy, several studies reported it. Warburg effect was firstly found to be implicated in resistance to irradiation and chemotherapy [@B37], [@B38]. After that, Moeller *et al.* observed that ionizing radiation induced reoxygenation, which caused oxidative stress and radioresistance effects via upregulation of the transcription factor - hypoxia inducible factor 1 (HIF-1) [@B39]-[@B40]. HIF-1 is known as a regulator of the majority of glycolytic enzymes [@B41]. In the current study, we demonstrated over-expression of Aldolase B, a key enzyme of glycolysis, was significantly associated with poor response to CCRT. Therefore, increase of glycolytic activity or glycolytic enzymes in cancer cells may be an indicator for resistance to radiotherapy and chemotherapy, maybe via upregulation of HIF-1.

In conclusion, we demonstrated the significantly negative correlation between over-expression of Aldolase B and clinical and pathological parameters, such as pre- and post-treatment disease advancement, lymphovascular and perineural invasion, and less responsiveness to neoadjuvant CCRT in rectal cancer. Furthermore, high expression of Aldolase B in rectal adenocarcinoma was not only significantly associated with shorter disease-specific, local recurrent-free and metastasis-free survival intervals in univariate analysis, but also an independent prognostic biomarker predicting lower disease-specific and metastasis-free survival rates. The results indicated Aldolase B (ALDOB), both a key enzyme in glycolysis and positive regulator of canonical Wnt/β-catenin signaling pathway, could be an independent prognostic factor and even a potential target for new strategies of treatment for patients with rectal cancers. More investigations to clarify the detailed biological and molecular pathway of Aldolase B are necessary.
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![**Analysis of gene expression in rectal cancers with preoperative chemoradiation therapy by using a published transcriptome dataset (GSE35452).** Conducting a clustering analysis of genes by focusing on glycolysis (GO:0006096) revealed that *ALDOB* is the most significantly up-regulated genes in non-responder comparing with responder. Tumors classified as responder (yellow) or non-responder (blue) are illustrated at the top of the heat map, and the up-regulation and down-regulation of gene expression are represented as a continuum of brightness of red or green, respectively. Tumors with unchanged transcriptional level are in black.](jcav08p1197g001){#F1}

![**ALDOB (Aldolase B) immunostain** on representative sections showed **(A)** no expression in normal colonic mucosa, **(B)** low ALDOB immunoreactivity in tumors with high tumor regression grade after preoperative chemoradiation therapy, and **(C)** high ALDOB immunoreactivity in tumors with low tumor regression grade.](jcav08p1197g002){#F2}

![**Kaplan-Meier survival curves** demonstrated significant prognostic impact of ALDOB expression on disease-specific survival (*P* \< .0001), local recurrence-free survival (*P* = .0075) and metastasis-free survival (*P* = .0005).](jcav08p1197g003){#F3}

###### 

Significantly deregulated genes associated with glycolysis (GO:0006096) based on CCRT response in rectal cancer

  Probe          Comparison log~2~ ratio   Comparison *P*-value   Gene Symbol   Gene Name                           Biological Process                                                                                                                                                               Molecular Function
  -------------- ------------------------- ---------------------- ------------- ----------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  217238_s\_at   1.1475                    0.0002                 *ALDOB*       aldolase B; fructose-bisphosphate   fructose metabolic process, glycolysis, metabolic process                                                                                                                        catalytic activity, fructose-bisphosphate aldolase activity, lyase activity
  204705_x\_at   1.1092                    \<0.0001               *ALDOB*       aldolase B; fructose-bisphosphate   fructose metabolic process, glycolysis, metabolic process                                                                                                                        catalytic activity, fructose-bisphosphate aldolase activity, lyase activity
  211357_s\_at   0.9714                    0.0004                 *ALDOB*       aldolase B; fructose-bisphosphate   fructose metabolic process, glycolysis, metabolic process                                                                                                                        catalytic activity, fructose-bisphosphate aldolase activity, lyase activity
  204704_s\_at   0.3209                    0.0098                 *ALDOB*       aldolase B; fructose-bisphosphate   fructose metabolic process, glycolysis, metabolic process                                                                                                                        catalytic activity, fructose-bisphosphate aldolase activity, lyase activity
  1558365_at     -0.4005                   0.0049                 *PGK1*        phosphoglycerate kinase 1           glycolysis, phosphorylation                                                                                                                                                      ATP binding, kinase activity, nucleotide binding, phosphoglycerate kinase activity, transferase activity
  213564_x\_at   -0.3606                   0.0045                 *LDHB*        lactate dehydrogenase B             anaerobic glycolysis, anti-apoptosis, apoptosis, cellular carbohydrate metabolic process, glycolysis, protein folding, tricarboxylic acid cycle intermediate metabolic process   Hsp70/Hsc70 protein regulator activity, L-lactate dehydrogenase activity, oxidoreductase activity, oxidoreductase activity; acting on the CH-OH group of donors; NAD or NADP as acceptor, protein binding

###### 

Relationships between ALDOB expression and clinicopathological factors in rectal cancer patients receiving preoperative CCRT

  Parameter                             No.   ALDOB Expression   *P*-value   
  ------------------------- ----------- ----- ------------------ ----------- -----------
  Gender                    Male        108   55                 53          0.752
                            Female      64    31                 33          
  Age                       \<70        106   52                 54          0.754
                            ≥70         66    34                 32          
  Pre-CCRT cT stage         cT1-2       81    43                 38          0.445
                            cT3-4       91    43                 48          
  Pre-CCRT cN stage         cN0         125   72                 53          0.001\*
                            cN1-2       47    14                 33          
  Pre-CCRT CEA              ≤5 ng/ml    114   63                 51          0.053
                            \>5 ng/ml   58    23                 35          
  Post-CCRT pT stage        pT0-2       86    53                 33          0.002\*
                            pT3-4       86    33                 53          
  Post-CCRT pN stage        pN0         123   76                 47          \<0.001\*
                            pN1-2       49    10                 39          
  Lymphovascular invasion   Absent      157   83                 74          0.015\*
                            Present     15    3                  12          
  Perineural invasion       Absent      167   86                 81          0.023\*
                            Present     5     0                  5           
  Tumor regression grade    Grade 0-1   37    12                 25          \<0.001\*
                            Grade 2-3   118   59                 59          
                            Grade 4     17    15                 2           

\*, statistically significant

###### 

Univariate log-rank analysis for important clinicopathological variables and ALDOB expression

  Parameter                             No. of case   Disease-specific survival   Local recurrence-free survival   Metastasis-free survival                                 
  ------------------------- ----------- ------------- --------------------------- -------------------------------- -------------------------- ---------- ---- ---------- -- --
  Gender                    Male        108           20                          0.9026                           7                          0.2250     17   0.3520        
                            Female      64            11                                                           20                                    14                 
  Age                       \<70        106           19                          0.8540                           18                         0.6615     20   0.7427        
                            ≥70         66            12                                                           9                                     11                 
  Pre-CCRT cT stage         cT1-2       81            10                          0.0776                           10                         0.2261     11   0.1745        
                            cT3-4       91            21                                                           17                                    20                 
  Pre-CCRT cN stage         cN0         125           19                          0.0711                           15                         0.0070\*   19   0.0973        
                            cN1-2       47            21                                                           12                                    12                 
  Pre-CCRT CEA              ≤5 ng/ml    114           15                          0.0216\*                         13                         0.0179\*   17   0.1460        
                            \>5 ng/ml   58            16                                                           14                                    14                 
  Post-CCRT pT stage        pT0-2       86            7                           0.0006\*                         7                          0.0040\*   8    0.0033\*      
                            pT3-4       86            24                                                           20                                    23                 
  Post-CCRT pN stage        pN0         123           21                          0.5998                           16                         0.1320     20   0.4634        
                            pN1-2       49            10                                                           11                                    11                 
  Lymphovascular invasion   Absent      157           25                          0.0184\*                         21                         0.0028\*   27   0.4470        
                            Present     15            6                                                            6                                     4                  
  Perineural invasion       Absent      167           29                          0.2559                           25                         0.0940     30   0.9083        
                            Present     5             2                                                            2                                     1                  
  Tumor regression grade    Grade 0-1   37            13                          0.0038\*                         10                         0.0090\*   14   0.0006\*      
                            Grade 2-3   118           17                                                           17                                    16                 
                            Grade 4     17            1                                                            0                                     1                  
  ALDOB expression          Low Exp.    86            5                           \<0.0001\*                       8                          0.0075\*   7    0.0005\*      
                            High Exp.   86            26                                                           19                                    24                 
                                                                                                                                                                            

\*, statistically significant

###### 

Multivariate survival analysis

  Parameter                 Disease-specific survival   Local recurrence-free survival   Metastasis-free survival                                                          
  ------------------------- --------------------------- -------------------------------- -------------------------- ------- -------------- --------- ------- ------------- ---------
  Tumor regression grade    2.101                       1.001-4.425                      0.050\*                    2.762   1.241-6.173    0.013\*   2.242   1.092-4.587   0.028\*
  ALDOB expression          3.462                       1.263-9.495                      0.016\*                    1.372   0.550-3.422    0.498     2.846   1.190-6.808   0.019\*
  Lymphovascular invasion   2.401                       0.896-6.435                      0.082                      3.662   1.191-11.264   0.024\*   \-      \-            \-
  Pre-CCRT CEA              1.971                       0.930-4.177                      0.076                      2.496   1.061-5.876    0.036\*                         
  Post-CCRT pT stage        1.882                       0.761-4.658                      0.171                      1.579   0.627-3.978    0.333     1.819   0.766-4.321   0.175
  Pre-CCRT cN stage         \-                          \-                               \-                         1.534   0.643-3.660    0.845     \-      \-            \-

HR, hazard ratio; CI, confidence interval; \*, statistically significant
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